Share on StockTwits

Immunomedics (NASDAQ:IMMU) issued its quarterly earnings data on Monday. The company reported ($0.13) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.12) by $0.01, AmericanBankingNews.com reports. The company had revenue of $1.20 million for the quarter, compared to the consensus estimate of $1.20 million.

Immunomedics (NASDAQ:IMMU) traded up 3.49% during mid-day trading on Monday, hitting $3.56. 793,984 shares of the company’s stock traded hands. Immunomedics has a 52-week low of $3.04 and a 52-week high of $7.35. The stock’s 50-day moving average is $3.37 and its 200-day moving average is $3.91. The company’s market cap is $297.3 million.

Immunomedics, Inc is a biopharmaceutical company focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases.

Receive News & Ratings for Immunomedics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.